BrainStorm backs off plan to profit from ‘right-to-try,’ STAT says

BrainStorm Cell Therapeutics’ CEO Chaim Lebovitz previously had told Bloomberg that the company planned by take advantage of the new “right-to-try” law by selling its unapproved ALS treatment, NurOwn, to patients who could afford it, but the company has walked back that plan following heavy criticism, reported STAT’s Adam Feuerstein.

https://bit.ly/2KbS9zd